Quantitative evaluation and obstacle factor diagnosis of drug regulatory capacity in China.
- Published in:
- PLoS ONE, 2025, v. 20, n. 6, p. 1, doi. 10.1371/journal.pone.0325924
- By:
- Publication type:
- Article
Works matching DE "DRUG laws"
Results: 3320
1
2
Pharmacopoeias, Drug Regulation, and Empires. Making Medicines Official in Britain's Imperial World, 1618–1968.
- Published in:
- 2025
- By:
- Publication type:
- Book Review
3
Suzetrigine.
- Published in:
- American Journal of Health-System Pharmacy, 2025, v. 82, n. 12, p. 635, doi. 10.1093/ajhp/zxaf054
- Publication type:
- Article
4
Counterfeit and Inefficient Medicines in Eastern Countries: Trends, Regulatory Challenges, and Strategic Solutions.
- Published in:
- Advances in Consumer Research, 2025, v. 2, n. 3, p. 340
- By:
- Publication type:
- Article
5
Applying Machine Learning Techniques to Predict Drug-Related Side Effect: A Policy Brief.
- Published in:
- Inquiry (00469580), 2025, v. 62, p. 1, doi. 10.1177/00469580251335805
- By:
- Publication type:
- Article
6
SCATrans: semantic cross-attention transformer for drug–drug interaction predication through multimodal biomedical data.
- Published in:
- BMC Bioinformatics, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s12859-025-06165-6
- By:
- Publication type:
- Article
7
Rationality over convenience: The CDSCO's regulatory ban on irrational antidiabetic fixed-dose combinations in India and its clinical-pharmacological imperatives.
- Published in:
- International Journal of Diabetes in Developing Countries, 2025, v. 45, n. 2, p. 261, doi. 10.1007/s13410-025-01501-1
- By:
- Publication type:
- Article
8
State-Level Policies and Antibiotic Use for Pediatric Conjunctivitis.
- Published in:
- JAMA Pediatrics, 2025, v. 179, n. 6, p. 679, doi. 10.1001/jamapediatrics.2025.0478
- By:
- Publication type:
- Article
9
Introduction to Part II of the Special Issue Honoring Dr. Robert T. O'Neill's Contribution to Regulatory Statistical Science.
- Published in:
- Statistics in Biopharmaceutical Research, 2013, v. 5, n. 4, p. 280, doi. 10.1080/19466315.2013.852874
- By:
- Publication type:
- Article
10
THE REASON FOR THE SNEEZING: ORAL PHENYLEPHRINE AND THE FDA'S FOCUS ON SAFETY AT THE EXPENSE OF EFFECTIVENESS.
- Published in:
- Alabama Law Review, 2025, v. 76, n. 3, p. 623
- By:
- Publication type:
- Article
11
Correction to: A single upstream mutation of whiB7 underlies amikacin and clarithromycin resistance in Mycobacterium abscessusFree.
- Published in:
- 2025
- Publication type:
- Correction Notice
12
Addiction Lives: Shekhar Saxena.
- Published in:
- Addiction, 2025, v. 120, n. 7, p. 1484, doi. 10.1111/add.70034
- By:
- Publication type:
- Article
13
Pharmacopoeias, Drug Regulation, and Empires: Making Medicines Official in Britain's Imperial World, 1618–1968.
- Published in:
- 2025
- By:
- Publication type:
- Book Review
14
Scoping review on regulation, implementation and postmarket surveillance of medical devices.
- Published in:
- PLoS ONE, 2025, v. 20, n. 5, p. 1, doi. 10.1371/journal.pone.0325250
- By:
- Publication type:
- Article
15
NCCN Guidelines for NHL, Kidney Cancer Updated With New Drugs.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 14, p. 1221
- Publication type:
- Article
16
FDA Guidances for Early Human Testing of New Drugs.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 4, p. 325
- Publication type:
- Article
17
Regulatory Property: The New IP.
- Published in:
- Columbia Journal of Law & the Arts, 2016, v. 40, n. 1, p. 53
- By:
- Publication type:
- Article
18
IMAGING PEOPLE WHO USE DRUGS: HOW PARLIAMENTARY ACTORS PICTURE AND TELL STORIES ABOUT THE SUBJECTS OF DRUG LAW REFORM.
- Published in:
- Australasian Drama Studies, 2024, n. 84, p. 221
- By:
- Publication type:
- Article
19
Funding orphan medicinal products beyond price: sustaining an ecosystem.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
20
Competitive pricing within pharmaceutical classes: evidence on 'follow-on' drugs in Germany 1993-2008.
- Published in:
- European Journal of Health Economics, 2015, v. 16, n. 1, p. 73, doi. 10.1007/s10198-013-0555-3
- By:
- Publication type:
- Article
21
Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
- Published in:
- European Journal of Health Economics, 2014, v. 15, n. 6, p. 577, doi. 10.1007/s10198-013-0495-y
- By:
- Publication type:
- Article
22
Psychotropic Drugs Evaluated in the Context of Narcotic Drugs According to the New Turkish Criminal Law.
- Published in:
- Klinik Psikofarmakoloji Bulteni, 2010, v. 20, n. 4, p. 314, doi. 10.1080/10177833.2010.11790678
- Publication type:
- Article
23
Sürücülerde Alkol Dıflı Madde Kullanımının Saptanması: Neden? Nasıl? Nerede?
- Published in:
- Klinik Psikofarmakoloji Bulteni, 2008, v. 18, n. 3, p. 201
- By:
- Publication type:
- Article
24
The Role of Research Evidence in Drug Policy Development in Australia.
- Published in:
- Politicka Misao: Croatian Political Science Review, 2011, v. 48, n. 5, p. 141
- By:
- Publication type:
- Article
25
A word of caution.
- Published in:
- Indian Journal of Plastic Surgery, 2015, v. 48, n. 2, p. 215, doi. 10.4103/0970-0358.163067
- By:
- Publication type:
- Article
26
PSYCHEDELICS : A TEST CASE FOR THE LIBERTARIAN.
- Published in:
- Political Quarterly, 1981, v. 52, n. 2, p. 225, doi. 10.1111/j.1467-923X.1981.tb02799.x
- By:
- Publication type:
- Article
27
John Arbuthnot on the Regulation of Drugs and Medicines.
- Published in:
- Population & Development Review, 2012, v. 38, n. 3, p. 547, doi. 10.1111/j.1728-4457.2012.00516.x
- Publication type:
- Article
28
STAKEHOLDER ENGAGEMENT IN PHARMACEUTICAL REGULATION: CONNECTING TECHNICAL EXPERTISE AND LAY KNOWLEDGE IN RISK MONITORING.
- Published in:
- Public Administration, 2013, v. 91, n. 3, p. 696, doi. 10.1111/padm.12027
- By:
- Publication type:
- Article
29
THE INEXORABLE RISE IN THE UK NHS DRUGS BILL: RECENT POLICIES, FUTURE PROSPECTS.
- Published in:
- Public Administration, 1996, v. 74, n. 3, p. 393, doi. 10.1111/j.1467-9299.1996.tb00877.x
- By:
- Publication type:
- Article
30
Drug Safety Dominates DIA.
- Published in:
- Bio-IT World, 2005, v. 4, n. 8, p. 30
- By:
- Publication type:
- Article
31
GMP Compliance Goes Digital.
- Published in:
- Bio-IT World, 2005, v. 4, n. 4, p. 52
- By:
- Publication type:
- Article
32
PDMA Compliance in 12 Steps.
- Published in:
- Bio-IT World, 2004, v. 3, n. 1, p. 44
- By:
- Publication type:
- Article
33
Towards Photochromic Azobenzene‐Based Inhibitors for Tryptophan Synthase.
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 7, p. 2439, doi. 10.1002/chem.202004061
- By:
- Publication type:
- Article
34
Front Cover Image, Volume 45, Issue 1.
- Published in:
- Medicinal Research Reviews, 2025, v. 45, n. 1, p. i, doi. 10.1002/med.22094
- By:
- Publication type:
- Article
35
Quality, efficacy, safety—it is not enough!
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 9, p. 1425, doi. 10.1007/s00228-021-03110-3
- By:
- Publication type:
- Article
36
Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 7, p. 1057, doi. 10.1007/s00228-021-03096-y
- By:
- Publication type:
- Article
37
Impact of changes in controlled drugs legislation on benzodiazepine receptor agonist prescribing in Ireland: a repeated cross-sectional study.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 6, p. 903, doi. 10.1007/s00228-020-03063-z
- By:
- Publication type:
- Article
38
Clinical evidence supporting the marketing authorization of biosimilars in Europe.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 4, p. 557, doi. 10.1007/s00228-019-02805-y
- By:
- Publication type:
- Article
39
Consequences of the new zolpidem prescription regulations: a cohort study from the French national healthcare database.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 1, p. 89, doi. 10.1007/s00228-019-02737-7
- By:
- Publication type:
- Article
40
Presentations to the emergency department with non-medical use of benzodiazepines and Z-drugs: profiling and relation to sales data.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 1, p. 77, doi. 10.1007/s00228-018-2550-1
- By:
- Publication type:
- Article
41
Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 1, p. 1, doi. 10.1007/s00228-018-2542-1
- By:
- Publication type:
- Article
42
The race for drug approvals: hasten slowly?
- Published in:
- European Journal of Clinical Pharmacology, 2018, v. 74, n. 9, p. 1197, doi. 10.1007/s00228-018-2490-9
- By:
- Publication type:
- Article
43
Response to the letter to the Editor regarding Zeukeng et al.’s article A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
- Published in:
- European Journal of Clinical Pharmacology, 2018, v. 74, n. 9, p. 1199, doi. 10.1007/s00228-018-2486-5
- By:
- Publication type:
- Article
44
The patient’s safety and access to experimental drugs after the termination of clinical trials: regulations and trends.
- Published in:
- European Journal of Clinical Pharmacology, 2018, v. 74, n. 8, p. 1001, doi. 10.1007/s00228-018-2474-9
- By:
- Publication type:
- Article
45
From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.
- Published in:
- European Journal of Clinical Pharmacology, 2017, v. 73, n. 7, p. 901, doi. 10.1007/s00228-017-2240-4
- By:
- Publication type:
- Article
46
Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations.
- Published in:
- European Journal of Clinical Pharmacology, 2017, v. 73, n. 4, p. 479, doi. 10.1007/s00228-016-2186-y
- By:
- Publication type:
- Article
47
An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe.
- Published in:
- European Journal of Clinical Pharmacology, 2015, v. 71, n. 10, p. 1237, doi. 10.1007/s00228-015-1904-1
- By:
- Publication type:
- Article
48
Sex as a variable in medicines assessment reports for licensing in the European Union. Can gender bias be excluded?
- Published in:
- European Journal of Clinical Pharmacology, 2014, v. 70, n. 5, p. 519, doi. 10.1007/s00228-014-1646-5
- By:
- Publication type:
- Article
49
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 4, p. 1009, doi. 10.1007/s00228-012-1423-2
- By:
- Publication type:
- Article
50
The status of paediatric medicines initiatives around the world-what has happened and what has not?
- Published in:
- European Journal of Clinical Pharmacology, 2012, v. 68, n. 1, p. 1, doi. 10.1007/s00228-011-1089-1
- By:
- Publication type:
- Article